ICSMA-23-047-01

Vulnerability from csaf_cisa - Published: 2023-02-16 00:00 - Updated: 2023-02-27 13:27
Summary
BD Alaris Infusion Central
Notes
CISA Disclaimer: This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov
Legal Notice: All information products included in https://us-cert.cisa.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.
Note on Affected Status for end-users: Users who use BD Alaris PCU 8015 or BD Alaris Systems Manager are not impacted by this vulnerability.
Update Summary: This updated advisory is a follow-up to the original advisory titled ICSMA-23-047-01 BD Alaris Infusion Central that was published February 16, 2023, to the ICS webpage on www.cisa.gov/uscert.
Risk evaluation: Successful exploitation of this vulnerability could allow an attacker to obtain the database installation password and gain access to the Alaris Infusion Central database, resulting in disclosure of resident personal data.
Critical infrastructure sectors: Healthcare and Public Health
Countries/areas deployed: Deployed outside the U.S.
Company headquarters location: United States
Recommended Practices: CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
Recommended Practices: CISA also provides a section for control systems security recommended practices on the ICS webpage at cisa.gov/ics. Several CISA products detailing cyber defense best practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Recommended Practices: Additional mitigation guidance and recommended practices are publicly available on the ICS webpage at cisa.gov/ics in the technical information paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Recommended Practices: Organizations observing suspected malicious activity should follow established internal procedures and report findings to CISA for tracking and correlation against other incidents.
Recommended Practices: CISA also recommends users take the following measures to protect themselves from social engineering attacks: Do not click web links or open unsolicited attachments in email messages; Refer to Recognizing and Avoiding Email Scams (https://us-cert.cisa.gov/sites/default/files/publications/emailscams_0905.pdf) for more information on avoiding email scams; Refer to Avoiding Social Engineering and Phishing Attacks (https://us-cert.cisa.gov/ncas/tips/ST04-014) for more information on social engineering attacks.
Recommended Practices: Do not click web links or open attachments in unsolicited email messages.
Recommended Practices: Refer to Recognizing and Avoiding Email Scams for more information on avoiding email scams.
Recommended Practices: Refer to Avoiding Social Engineering and Phishing Attacks for more information on social engineering attacks.
Recommended Practices: No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.
CWE-257 - Storing Passwords in a Recoverable Format
Vendor Fix BD is directly reaching out to the small group of customers who may be impacted by this vulnerability to initiate remediation.
Mitigation Change passwords periodically per best security practice.
Mitigation Ensure physical access controls are in place; only authorized administrators should have access to the Alaris Infusion Central server.
Vendor Fix For additional information, refer to BD's security bulletin. https://www.bd.com/en-us/about-bd/cybersecurity/b…
Acknowledgments
BD

{
  "document": {
    "acknowledgments": [
      {
        "organization": "BD",
        "summary": "reporting this vulnerability to CISA"
      }
    ],
    "category": "csaf_security_advisory",
    "csaf_version": "2.0",
    "distribution": {
      "text": "Disclosure is not limited",
      "tlp": {
        "label": "WHITE",
        "url": "https://us-cert.cisa.gov/tlp/"
      }
    },
    "lang": "en-US",
    "notes": [
      {
        "category": "general",
        "text": "This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov",
        "title": "CISA Disclaimer"
      },
      {
        "category": "legal_disclaimer",
        "text": "All information products included in https://us-cert.cisa.gov/ics are provided \"as is\" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.",
        "title": "Legal Notice"
      },
      {
        "category": "other",
        "text": "Users who use BD Alaris PCU 8015 or BD Alaris Systems Manager are not impacted by this vulnerability.",
        "title": "Note on Affected Status for end-users"
      },
      {
        "category": "summary",
        "text": "This updated advisory is a follow-up to the original advisory titled ICSMA-23-047-01 BD Alaris Infusion Central that was published February 16, 2023, to the ICS webpage on www.cisa.gov/uscert.",
        "title": "Update Summary"
      },
      {
        "category": "summary",
        "text": "Successful exploitation of this vulnerability could allow an attacker to obtain the database installation password and gain access to the Alaris Infusion Central database, resulting in disclosure of resident personal data.",
        "title": "Risk evaluation"
      },
      {
        "category": "other",
        "text": "Healthcare and Public Health",
        "title": "Critical infrastructure sectors"
      },
      {
        "category": "other",
        "text": "Deployed outside the U.S.",
        "title": "Countries/areas deployed"
      },
      {
        "category": "other",
        "text": "United States",
        "title": "Company headquarters location"
      },
      {
        "category": "general",
        "text": "CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "CISA also provides a section for control systems security recommended practices on the ICS webpage at cisa.gov/ics. Several CISA products detailing cyber defense best practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "Additional mitigation guidance and recommended practices are publicly available on the ICS webpage at cisa.gov/ics in the technical information paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "Organizations observing suspected malicious activity should follow established internal procedures and report findings to CISA for tracking and correlation against other incidents.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "CISA also recommends users take the following measures to protect themselves from social engineering attacks: Do not click web links or open unsolicited attachments in email messages; Refer to Recognizing and Avoiding Email Scams (https://us-cert.cisa.gov/sites/default/files/publications/emailscams_0905.pdf) for more information on avoiding email scams; Refer to Avoiding Social Engineering and Phishing Attacks (https://us-cert.cisa.gov/ncas/tips/ST04-014) for more information on social engineering attacks.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "Do not click web links or open attachments in unsolicited email messages.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "Refer to Recognizing and Avoiding Email Scams for more information on avoiding email scams.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "Refer to Avoiding Social Engineering and Phishing Attacks for more information on social engineering attacks.",
        "title": "Recommended Practices"
      },
      {
        "category": "general",
        "text": "No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.",
        "title": "Recommended Practices"
      }
    ],
    "publisher": {
      "category": "coordinator",
      "contact_details": "Email: CISAservicedesk@cisa.dhs.gov;\n Toll Free: 1-888-282-0870",
      "name": "CISA",
      "namespace": "https://www.cisa.gov/"
    },
    "references": [
      {
        "category": "self",
        "summary": "ICS Advisory ICSMA-23-047-01 JSON",
        "url": "https://raw.githubusercontent.com/cisagov/CSAF/develop/csaf_files/OT/white/2023/icsma-23-047-01.json"
      },
      {
        "category": "self",
        "summary": "ICS Advisory ICSMA-23-047-01 Web Version",
        "url": "https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01"
      },
      {
        "category": "external",
        "summary": "Recommended Practices",
        "url": "https://us-cert.cisa.gov/ics/Recommended-Practices"
      },
      {
        "category": "external",
        "summary": "Recommended Practices",
        "url": "https://cisa.gov/ics"
      },
      {
        "category": "external",
        "summary": "Recommended Practices",
        "url": "https://www.cisa.gov/uscert/sites/default/files/publications/emailscams0905.pdf"
      },
      {
        "category": "external",
        "summary": "Recommended Practices",
        "url": "https://www.cisa.gov/uscert/ncas/tips/ST04-014"
      }
    ],
    "title": "BD Alaris Infusion Central",
    "tracking": {
      "current_release_date": "2023-02-27T13:27:41.553636Z",
      "generator": {
        "engine": {
          "name": "CISA CSAF Generator",
          "version": "1.0.0"
        }
      },
      "id": "ICSMA-23-047-01",
      "initial_release_date": "2023-02-16T00:00:00.000000Z",
      "revision_history": [
        {
          "date": "2023-02-16T00:00:00.000000Z",
          "legacy_version": "1",
          "number": "1",
          "summary": "Previous Publication Date"
        },
        {
          "date": "2023-02-27T13:27:41.553636Z",
          "legacy_version": "2",
          "number": "2",
          "summary": "CSAF Update A Date"
        }
      ],
      "status": "final",
      "version": "2"
    }
  },
  "product_tree": {
    "branches": [
      {
        "branches": [
          {
            "branches": [
              {
                "category": "product_version_range",
                "name": "\u003e= 1.1 | \u003c= 1.3.2",
                "product": {
                  "name": "Alaris Infusion Central software: versions 1.1 to 1.3.2, which are not sold in the U.S.",
                  "product_id": "CSAFPID-0001"
                }
              }
            ],
            "category": "product_name",
            "name": "Alaris Infusion Central software"
          }
        ],
        "category": "vendor",
        "name": "Becton, Dickinson and Company (BD)"
      }
    ]
  },
  "vulnerabilities": [
    {
      "cve": "CVE-2022-47376",
      "cwe": {
        "id": "CWE-257",
        "name": "Storing Passwords in a Recoverable Format"
      },
      "notes": [
        {
          "category": "summary",
          "text": "Alaris Infusion Central versions 1.1-1.3.2 may contain a recoverable password after installation, which could allow an attacker to disclose or tamper with resident personal data. Patient health data is not stored in the database, although some side installations may choose to store personal data. CVE-2022-47376 has been assigned to this vulnerability. A CVSS v3 base score of 7.3 has been assigned; the CVSS vector string is (CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L).",
          "title": "Vulnerability Summary"
        }
      ],
      "product_status": {
        "known_affected": [
          "CSAFPID-0001"
        ]
      },
      "references": [
        {
          "category": "external",
          "summary": "web.nvd.nist.gov",
          "url": "http://web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2022-47376"
        },
        {
          "category": "external",
          "summary": "www.first.org",
          "url": "https://www.first.org/cvss/calculator/3.0#CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L"
        }
      ],
      "remediations": [
        {
          "category": "vendor_fix",
          "details": "BD is directly reaching out to the small group of customers who may be impacted by this vulnerability to initiate remediation.",
          "product_ids": [
            "CSAFPID-0001"
          ]
        },
        {
          "category": "mitigation",
          "details": "Change passwords periodically per best security practice.",
          "product_ids": [
            "CSAFPID-0001"
          ]
        },
        {
          "category": "mitigation",
          "details": "Ensure physical access controls are in place; only authorized administrators should have access to the Alaris Infusion Central server.",
          "product_ids": [
            "CSAFPID-0001"
          ]
        },
        {
          "category": "vendor_fix",
          "details": "For additional information, refer to BD\u0027s security bulletin.",
          "product_ids": [
            "CSAFPID-0001"
          ],
          "url": "https://www.bd.com/en-us/about-bd/cybersecurity/bulletin/alaris-infusion-central-recoverable-password-vulnerability"
        }
      ],
      "scores": [
        {
          "cvss_v3": {
            "baseScore": 7.3,
            "baseSeverity": "HIGH",
            "vectorString": "CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L",
            "version": "3.1"
          },
          "products": [
            "CSAFPID-0001"
          ]
        }
      ]
    }
  ]
}


Log in or create an account to share your comment.




Tags
Taxonomy of the tags.


Loading…

Loading…

Loading…

Sightings

Author Source Type Date

Nomenclature

  • Seen: The vulnerability was mentioned, discussed, or observed by the user.
  • Confirmed: The vulnerability has been validated from an analyst's perspective.
  • Published Proof of Concept: A public proof of concept is available for this vulnerability.
  • Exploited: The vulnerability was observed as exploited by the user who reported the sighting.
  • Patched: The vulnerability was observed as successfully patched by the user who reported the sighting.
  • Not exploited: The vulnerability was not observed as exploited by the user who reported the sighting.
  • Not confirmed: The user expressed doubt about the validity of the vulnerability.
  • Not patched: The vulnerability was not observed as successfully patched by the user who reported the sighting.


Loading…

Detection rules are retrieved from Rulezet.

Loading…

Loading…